We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Medtronic PLC | NYSE:MDT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.49 | 0.62% | 79.74 | 79.85 | 78.95 | 79.42 | 5,023,165 | 00:18:30 |
From Apr 2019 to Apr 2024
By Chris Wack
Medtronic PLC (MDT) said Tuesday it has received Breakthrough Device designation from the U.S. Food and Drug Administration for the Medtronic Fully Implantable Left Ventricular Assist Device, or LVAD, for patients with advanced heart failure, currently in development.
The medical technology company said the FDA will provide Medtronic with priority review and interactive communication regarding device development and clinical trial protocols, through to commercialization decisions.
Medtronic's LVAD systems include an implanted heart pump to increase the amount of blood that circulates through the body.
Medtronic said its fully implantable LVAD is in early-stage research and development, and isn't available for sale anywhere in the world.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 29, 2019 12:32 ET (16:32 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Medtronic Chart |
1 Month Medtronic Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
